Performance of BIOFIRE FILMARRAY pneumonia panel in suspected pneumonia: insights from a real-world study
- PMID: 40401975
- PMCID: PMC12210945
- DOI: 10.1128/spectrum.00571-25
Performance of BIOFIRE FILMARRAY pneumonia panel in suspected pneumonia: insights from a real-world study
Abstract
Pneumonia may be caused by a diverse group of microorganisms; however, a microbiologic diagnosis is not universally made. Molecular tests such as the BIOFIRE FILMARRAY Pneumonia Panel (BF-PP) offer the possibility of rapid identification of potential pneumonia pathogens. This retrospective analysis was conducted as a sub-study of a recently published randomized controlled trial. Specimens from patients with suspected pneumonia were tested by the BF-PP, with results compared to cultures. The overall BF-PP positivity rate was 44.8% (252/563), and was higher [64.6% (164/254)] in specimens from patients ultimately diagnosed with pneumonia. Discrepancies between the BF-PP and cultures were most common for Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus agalactiae. Positive percent agreement (PPA) and negative percent agreement (NPA) between the BF-PP and culture were 91.4% (CI 86.3%-94.9%) and 83.6% (CI 79.5%-87.2%), respectively. For most bacteria, a correlation between high genomic abundance (genomic copies/mL) reported from the BF-PP and culture growth abundance was found. In specimens from patients ultimately diagnosed with pneumonia, clinical consistency-assessed based on whether BF-PP results aligned with associated culture results-was 79.9% and was highest for bronchoalveolar lavage fluid specimens. The BF-PP has reliable analytical performance and offers the potential advantage over conventional cultures of providing higher detection rates and more rapid results. Interestingly, despite the use of this advanced molecular diagnostic tool, one-third of pneumonia cases remained without a microbiologic etiology.IMPORTANCEThis study evaluates the BIOFIRE FILMARRAY Pneumonia Panel by comparing its performance to conventional cultures in a real-world patient population (including patients ultimately diagnosed as not having pneumonia) using different types of specimens. Findings show a higher detection rate of microorganisms with the panel compared to cultures, suggesting that this test could aid in tailoring treatments for pneumonia. However, challenges remain and require further study, including distinguishing true pathogens from colonizing microorganisms and determinig why one-third of patients diagnosed with pneumonia still lacked a microbiologic etiology.
Keywords: BIOFIRE; analytical performance; concordance; negative percent agreement; pneumonia; positive percent agreement.
Conflict of interest statement
R.P. reports grants from MicuRx Pharmaceuticals and bioMérieux and is a consultant to PhAST, Day Zero Diagnostics, DEEPULL DIAGNOSTICS, S.L., Nostics, HealthTrackRx, bioMérieux, and CARB-X. R.P. has a patent on
Similar articles
-
Rapid microbial evaluation of acute exacerbations of bronchiectasis using FilmArray Pneumonia plus Panel in a real-world setting.Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251341751. doi: 10.1177/17534666251341751. Epub 2025 Jun 21. Ther Adv Respir Dis. 2025. PMID: 40543018 Free PMC article.
-
Comparative performance of biofire pneumonia panel and standard culture-based methods for diagnosing pneumonia in critically ill patients: Impact on antibiotic stewardship.Indian J Med Microbiol. 2024 May-Jun;49:100564. doi: 10.1016/j.ijmmb.2024.100564. Epub 2024 Apr 22. Indian J Med Microbiol. 2024. PMID: 38649113
-
Molecular versus conventional assay for diagnosis of hospital-acquired pneumonia in critically ill patients: a single center experience.J Infect Chemother. 2025 Aug;31(8):102754. doi: 10.1016/j.jiac.2025.102754. Epub 2025 Jun 11. J Infect Chemother. 2025. PMID: 40513663
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3. Cochrane Database Syst Rev. 2022. PMID: 35866452 Free PMC article.
References
-
- Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG. 2019. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the american thoracic society and infectious diseases society of America. Am J Respir Crit Care Med 200:e45–e67. doi: 10.1164/rccm.201908-1581ST - DOI - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous